for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aethlon Medical, Inc.

AEMD.OQ

Latest Trade

4.80USD

Change

-0.05(-1.03%)

Volume

2,449

Today's Range

4.76

 - 

5.02

52 Week Range

3.08

 - 

26.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.85
Open
5.02
Volume
2,449
3M AVG Volume
0.43
Today's High
5.02
Today's Low
4.76
52 Week High
26.10
52 Week Low
3.08
Shares Out (MIL)
1.33
Market Cap (MIL)
6.45
Forward P/E
-1.20
Dividend (Yield %)
--

Next Event

Aethlon Medical Inc at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Aethlon Announces Reverse Stock Split

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

Aethlon Medical Says National Cancer Institute Awarded Co SBIR Phase 2 Contract For Topic 359

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Industry

Biotechnology & Drugs

Contact Info

9635 Granite Ridge Dr Ste 100

+1.858.4597800

https://www.aethlonmedical.com/

Executive Leadership

Charles J Fisher

Independent Chairman and Director

Timothy C. Rodell

Interim Chief Executive Officer, Director

James B. Frakes

Chief Financial Officer, Senior Vice President - Finance, IR Contact Officer

Edward G. Broenniman

Independent Director

Guy F. Cipriani

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-6.900

2019

-5.100

2020(E)

-4.050
Price To Earnings (TTM)
--
Price To Sales (TTM)
58.61
Price To Book (MRQ)
5.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
77.95
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-194.08
Return on Equity (TTM)
-152.01

Latest News

Latest News

BRIEF-Aethlon Medical Participates In Informational Meeting With FDA​

* AETHLON MEDICAL SAYS ON MARCH 20, CO PARTICIPATED IN AN INFORMATIONAL MEETING WITH FDA - SEC FILING

BRIEF-Aethlon Medical Announces Fiscal 2018 Third Quarter Results

* AETHLON MEDICAL ANNOUNCES FISCAL 2018 THIRD QUARTER RESULTS

BRIEF-Aethlon Medical Says Granted U.S. Patent That Broadens Protection For The Aethlon Hemopurifier

* AETHLON MEDICAL ANNOUNCES ALLOWANCE OF U.S. PATENT THAT BROADENS PROTECTION FOR THE AETHLON HEMOPURIFIER® TO TREAT VIRAL INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Sabrina Johnson Joins Aethlon Medical's Board Of Directors

* SABRINA MARTUCCI JOHNSON JOINS AETHLON MEDICAL'S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical Names Dr. Charles J. Fisher Chairman Of The Board

* AETHLON MEDICAL NAMES DR. CHARLES J. FISHER CHAIRMAN OF THE BOARD Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical announces second quarter results

* Aethlon Medical announces fiscal 2018 second quarter results

BRIEF-AETHLON MEDICAL ANNOUNCES PRODUCTION COLLABORATION WITH IBIO INC

* AETHLON MEDICAL ANNOUNCES LARGE-SCALE PRODUCTION COLLABORATION

BRIEF-IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

* IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

BRIEF-Intracoastal Capital reports 5.7 pct passive stake in Aethlon Medical

* Intracoastal Capital LLC reports 5.7 percent passive stake in Aethlon Medical Inc as of Oct 2 - SEC filing Source : (http://bit.ly/2ybZng4) Further company coverage:

BRIEF-Aethlon Medical Receives expedited access pathway designation from FDA

* Aethlon Medical receives expedited access pathway designation from FDA to accelerate U.S. access to the hemopurifier as a treatment for life-threatening viruses Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical received formal receipt from FDA for expedited access pathway program submission

* On Aug 14, co received formal receipt from the U.S. FDA for expedited access pathway program submission

BRIEF-Aethlon Medical reports Q1 loss per share $0.21

* Aethlon Medical announces fiscal 2018 first quarter results

BRIEF-Aethlon Medical Inc files for stock offering of up to $13.3 mln - SEC filing

* Aethlon Medical Inc files for common stock offering of up to $13.3 million - SEC filing Source text: (http://bit.ly/2vgQRdw) Further company coverage:

BRIEF-Aethlon Medical ‍announces grant of U.S. patent

* Aethlon Medical Inc - announces grant of a U.S. Patent protecting methods of capturing MHC antigen associated exosomes Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical plans to submit expedited access pathway program submission to FDA

* Aethlon Medical Inc - now plans to submit an expedited access pathway program submission to FDA

BRIEF-Empery Asset Management LP reports 8.79 pct passive stake in Aethlon Medical as of March 22 - SEC Filing

* Empery Asset Management LP reports 8.79 percent passive stake in Aethlon Medical Inc as of March 22 - SEC Filing Source text: [http://bit.ly/2naxvz2] Further company coverage:

BRIEF-Aethlon Medical enters into securities purchase agreement with institutional investors

* On March 22, co entered into a securities purchase agreement with certain institutional investors - sec filing

BRIEF-Aethlon Medical announces the conclusion of hemopurifier clinical study

* Aethlon Medical announces the conclusion of hemopurifier clinical study

BRIEF-Aethlon Medical reports Q2 loss per share $0.29

* Aethlon Medical Inc says recorded revenues of $387 thousand from its government contracts in q2 of fiscal 2017 compared to $188 thousand in q2 of fiscal

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up